BofA upgraded Vir Biotechnology (VIR) to Buy from Neutral with a price target of $14, up from $12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Strategic Advancements and Strong Pipeline Drive Buy Rating
- Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating
- Vir Biotechnology’s Earnings Call Highlights Progress and Challenges
- Vir Biotechnology’s Strong Clinical Pipeline and Financial Position Reinforce Buy Rating
- Vir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating